What makes clinical evidence trustworthy?

A misplaced biological sample. An adverse event not reported on time. A deviation in the dispensing of an investigational medicinal product. A critical data point entered incorrectly. 

Any of these situations could compromise the quality of a clinical trial, affect patient safety, or put years of work and research at risk. 

This is precisely why, behind every result, there is a system of controls, processes and professionals whose role is to prevent these risks from becoming reality.

Protocol approval marks the start of a critical phase: translating scientific and regulatory requirements into a controlled and reproducible operational framework. 

Every study relies on procedures, tools and oversight plans designed to ensure data quality and regulatory compliance. 

Tools such as the eCRF incorporate specific validations and edit checks to identify inconsistencies from the moment data are entered. In contrast, documents such as the Data Management Plan, Monitoring Plan and risk assessments establish the framework for study oversight. 

Quality is not reviewed at the end. It is designed from the outset. 

Once a study is underway, data, issues and risks are monitored continuously to verify compliance with both the protocol and regulatory requirements. 

Every review and every follow-up activity shares the same objective: identifying deviations early and taking action before they have an impact on the study.

Clinical trials do not rely solely on procedures. They also depend on the people responsible for ensuring that those procedures are implemented correctly. 

Investigators and their teams balance clinical research with patient care, teaching commitments and numerous other healthcare responsibilities. 

In this context, obtaining the timely completion of outstanding actions, resolving data queries or securing critical documentation within defined timelines is not always straightforward. 

An essential part of this work involves coordinating participating sites in an environment characterised by significant clinical workloads and multiple competing priorities. 

This requires building trusted relationships, anticipating challenges and facilitating solutions without compromising regulatory compliance or study quality. 

Maintaining this balance between collaboration and accountability is one of the most important responsibilities of clinical trial oversight. 

In addition to day-to-day oversight, clinical trials incorporate numerous additional quality controls. 

These include internal reviews, data validation activities, reconciliations, pharmacovigilance checks, follow-up of corrective and preventive actions, and final verification processes before database lock and statistical analysis. 

These activities rarely appear in scientific publications or final study results. 

Yet they are essential to ensuring that conclusions are based on robust, traceable and reliable data. 

Digitalisation, risk-based monitoring, centralised data review and automation are transforming the way clinical studies are overseen. 

Some activities are now more efficient than they were only a few years ago. Others are being fundamentally redefined. 

As the landscape continues to evolve, maintaining current quality standards requires continuous development of knowledge, tools and approaches. 

The objective, however, remains the same: protecting patients and ensuring the quality of the evidence we generate. 

Technology can help identify signals, prioritise risks and improve efficiency. 

However, it is still people who interpret information, make decisions, resolve issues and ensure that every study meets the highest quality standards. 

Published results are only the visible part of the process. 

Behind them lie years of oversight, validation activities, data review, monitoring, risk management and coordination with participating sites. 

It is this work that makes it possible to trust the evidence generated. 

Trust does not appear in the results. It is built long before they are published. 

Quality is not a phase of the process nor a final check. It is a cross-functional discipline that accompanies a study from its design through to data analysis. 

Confidence in clinical evidence is built long before the results see the light of day. 

The Authors:

	Sonia Membrado Real World Data Consultant  Outcomes ‘10 – a PLG Company